We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Teva Gets 180-Day Exclusivity for Generic Risperdal
Teva Gets 180-Day Exclusivity for Generic Risperdal
February 6, 2009
The FDA has granted final approval to Teva Pharmaceutical Industries’ ANDA for its generic version of Ortho-McNeil-Janssen Pharmaceuticals’ antipsychotic agent Risperdal oral solution 1 mg/mL.